Ipatasertib is a selective (against a panel of 230 kinases) and potent pan-Akt inhibitor (IC50s: Akt1 = 5 nM, Akt2 = 18 nM, Akt3 = 8 nM).1 It displayed efficacy in xenograft models of prostate, breast, ovarian, colorectal, non-small cell lung, glioblastoma, and melanoma cancers.2 In clinical trials.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten